945 related articles for article (PubMed ID: 15778503)
1. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
2. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
3. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
4. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Semënov M; Tamai K; He X
J Biol Chem; 2005 Jul; 280(29):26770-5. PubMed ID: 15908424
[TBL] [Abstract][Full Text] [Related]
5. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
Lu W; Liu CC; Thottassery JV; Bu G; Li Y
Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
[TBL] [Abstract][Full Text] [Related]
6. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
7. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
[TBL] [Abstract][Full Text] [Related]
8. Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5.
Wang Z; Shu W; Lu MM; Morrisey EE
Mol Cell Biol; 2005 Jun; 25(12):5022-30. PubMed ID: 15923619
[TBL] [Abstract][Full Text] [Related]
9. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd.
Zhang Y; Wang Y; Li X; Zhang J; Mao J; Li Z; Zheng J; Li L; Harris S; Wu D
Mol Cell Biol; 2004 Jun; 24(11):4677-84. PubMed ID: 15143163
[TBL] [Abstract][Full Text] [Related]
10. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
[TBL] [Abstract][Full Text] [Related]
11. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
13. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
[TBL] [Abstract][Full Text] [Related]
14. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
15. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
16. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
Williams BO; Insogna KL
J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
[TBL] [Abstract][Full Text] [Related]
17. Second cysteine-rich domain of Dickkopf-2 activates canonical Wnt signaling pathway via LRP-6 independently of dishevelled.
Li L; Mao J; Sun L; Liu W; Wu D
J Biol Chem; 2002 Feb; 277(8):5977-81. PubMed ID: 11742004
[TBL] [Abstract][Full Text] [Related]
18. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
Semenov MV; He X
J Biol Chem; 2006 Dec; 281(50):38276-84. PubMed ID: 17052975
[TBL] [Abstract][Full Text] [Related]
19. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
Murrills RJ; Matteo JJ; Bhat BM; Coleburn VE; Allen KM; Chen W; Damagnez V; Bhat RA; Bex FJ; Bodine PV
J Cell Biochem; 2009 Dec; 108(5):1066-75. PubMed ID: 19746449
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
